-

Company Profile for Hope Biosciences Stem Cell Research Foundation

--(BUSINESS WIRE)--Hope Biosciences Stem Cell Research Foundation, administered through the Greater Houston Community Foundation, was founded to address the need to accelerate translational research in regenerative medicine so that therapies could be delivered to patients faster. The foundation is designed to not just support promising trials but to help develop innovative protocols using the latest technology to ultimately deliver high-quality data for quicker approvals. Today, the foundation is leading the effort in using mesenchymal stem cells to combat COVID-19, with three FDA authorized protocols for coronavirus. Current active protocols also include Cerebral Palsy, Parkinson’s Disease, Spinal Cord Injury, Traumatic Brain Injury, Alzheimer’s Disease, ALS and Severe Osteoarthritis. For more information, please visit https://www.hopebio.org/.

Company:

Hope Biosciences Stem Cell Research Foundation

 

 

Headquarters Address:

16700 Creekbend Dr

 

Sugar Land, TX 77478

 

 

Main Telephone:

346-900-0340

 

 

Website:

www.hopebio.org

 

 

Type of Organization:

Non-profit

 

 

Industry:

Research & Science

 

 

Key Executives:

President: Donna Chang

 

 

Public Relations

 

Contact:

Jan Shultis

Phone:

346-900-0340

Email:

jan@hopebio.org

 

Industry:

Hope Biosciences Stem Cell Research Foundation

Details
Headquarters: Sugar Land, Texas
CEO: Donna Chang
Employees: 12
Organization: NON
Release Versions
English
Hashtags
#biopharmaceutical
#biotechnology
#clinicaltrials
#drugdevelopment
#medicine
#pharmaceutical
#stemcellresearch
#stemcells
Social Media Profiles
Hope Biosciences Stem Cell Research Foundation
Hope Biosciences Stem Cell Research Foundation
Hope Biosciences Stem Cell Research Foundation
Hope Biosciences Stem Cell Research Foundation
Hope Biosciences Stem Cell Research Foundation
More News From Hope Biosciences Stem Cell Research Foundation

Hope Biosciences Research Foundation Opens Enrollment for FDA-Authorized Crohn’s Disease Stem Cell Trial

SUGAR LAND, Texas--(BUSINESS WIRE)--Hope Biosciences Research Foundation (HBRF) today announced the opening of enrollment for a Phase II clinical trial evaluating the potential of intravenously infused allogeneic, adipose-derived mesenchymal stem cells (HB-adMSCs) in adults living with Crohn’s Disease. The FDA-authorized study (NCT07077746) will enroll 46 participants at HBRF’s clinical research site in Sugar Land, Texas. This randomized, double-blind, placebo-controlled trial will assess wheth...

Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis

SUGAR LAND, Texas--(BUSINESS WIRE)--Hope Biosciences Research Foundation (HBRF) has received Food and Drug Administration (FDA) Authorization to administer Hope Biosciences’ adipose-derived mesenchymal (adult) stem cells (HB-adMSCs) to pediatric patients aged 2 – 16 years old suffering from juvenile idiopathic arthritis (JIA), the first FDA authorization for work in this cell type in this condition and HBRF’s first pediatric clinical trial. JIA, formerly known as “Juvenile Rheumatoid Arthritis,...

Hope Biosciences Research Foundation Reports Promising Phase II Trial Results for Stem Cell Therapy in Multiple Sclerosis

SUGAR LAND, Texas--(BUSINESS WIRE)--Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ adipose‑derived autologous mesenchymal stem cell therapy (HB-adMSCs) for patients with mild to moderate relapsing remitting multiple sclerosis (MS), a disease currently considered incurable that affects more than 2 million people worldwide and approximately 400,000 in the U.S....
Back to Newsroom